NEW YORK, June 20- Boehringer Ingelheim has signed a multi-site license for DoubleTwist’s Clustering and Alignment Tools (CAT), the companies announced Wednesday.
DoubleTwist declined to reveal the financial details of the agreement.
"We chose CAT not only for the quality of the technology, but also because we feel that DoubleTwist as a global company is best positioned to support the discovery efforts of our global research units," Bernd Wetzel, head of corporate division research and nonclinical development at Boehringer Ingelheim, said in a statement.
CAT organizes expressed sequence tags and mRNA sequences into full-length gene sequences, uses statistics to correct sequencing and cloning errors, and isolates and analyzes alternative splice forms.
Currently, over 30 companies subscribe to CAT, including Millenium Pharmaceuticals, Affymetrix, and Bristol-Myers Squibb, Oakland-based DoubleTwist said.